FREE STANDARD SHIPPING ON ORDERS $250+

Bacteriostatic Water

Shop

Bacteriostatic Water · Research brief

Is Tesamorelin Legal? (Regulatory Status Explained)

RP
Real Peptides Research TeamEditorial
Updated February 17, 202614 min read
58 WORDS

Short answer

Research from the FDA's Center for Drug Evaluation and Research shows that tesamorelin (brand name Egrifta) has maintained continuous approval status since November 2010—making it one of the few growth hormone-releasing hormone (GHRH) analogs with full regulatory clearance for medical use. The catch? That approval covers one specific indication: reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Key takeaways

  • Tesamorelin legal status under FDA approval is limited to prescription use for HIV-associated lipodystrophy—off-label prescribing is legal but removes manufacturer liability and insurance coverage.
  • Research-grade tesamorelin is legal when labeled and sold explicitly for laboratory research, not for human consumption, veterinary use, or clinical treatment.
  • The regulatory distinction between pharmaceutical and research-grade peptides hinges on intended use—marketing research peptides with therapeutic claims converts them into unapproved new drugs.
  • Pharmaceutical tesamorelin (Egrifta) undergoes cGMP manufacturing with full batch traceability; research-grade formulations bypass FDA drug approval but require accurate purity verification via HPLC and mass spectrometry.
  • Compounded tesamorelin from 503B facilities occupies a middle ground—legal when prescribed for legitimate medical use but lacking FDA approval as a drug product.
  • Purchasing research-grade tesamorelin is legal for laboratory use; administering it to humans violates federal regulations regardless of consent or research protocol framing.

Research from the FDA's Center for Drug Evaluation and Research shows that tesamorelin (brand name Egrifta) has maintained continuous approval status since November 2010—making it one of the few growth hormone-releasing hormone (GHRH) analogs with full regulatory clearance for medical use. The catch? That approval covers one specific indication: reducing excess abdominal fat in HIV-infected patients with lipodystrophy. We've sourced peptides for research institutions across multiple regulatory environments, and the gap between prescription tesamorelin legal frameworks and research-grade peptide compliance is where most confusion—and most compliance failures—happen.

Is tesamorelin legal in medical and research contexts?

Tesamorelin legal status depends entirely on context of use. FDA-approved tesamorelin (Egrifta, Egrifta SV) is legal for prescription use in treating HIV-associated lipodystrophy under physician supervision. Research-grade tesamorelin synthesized for laboratory use is legal when sourced from compliant suppliers, properly labeled for research purposes only, and used in non-clinical settings. Off-label human use of research-grade peptides violates federal regulations—the distinction between pharmaceutical and research-grade formulations determines legality.

Most peptide guides treat all tesamorelin as functionally identical. That's wrong. The FDA approval pathway for Egrifta involved Phase III randomized controlled trials with specific manufacturing standards, batch testing, and post-market surveillance requirements that research-grade peptides don't undergo. Research-grade tesamorelin serves biological research, cellular studies, and mechanism investigations—contexts where pharmaceutical-grade certification isn't required. This article covers the exact regulatory framework that determines tesamorelin legal status, the compliance distinctions between pharmaceutical and research-grade formulations, and what sourcing decisions mean for research applications versus clinical use.

Tesamorelin legal status in clinical medicine stems from FDA approval granted November 10, 2010, following two pivotal Phase III trials that demonstrated statistically significant reduction in visceral adipose tissue (VAT) in HIV patients with lipodystrophy. The approved indication is narrow—excess abdominal fat in the specific population of HIV-infected adults—and prescribing outside this indication constitutes off-label use, which remains legal under physician discretion but removes manufacturer liability and insurance coverage guarantees.

The mechanism behind tesamorelin involves binding to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary, stimulating endogenous growth hormone (GH) secretion in a pulsatile pattern that mimics natural physiological release. Unlike direct GH administration, tesamorelin preserves the body's negative feedback regulation—when GH levels rise sufficiently, hypothalamic somatostatin release suppresses further secretion, preventing the supraphysiological spikes associated with exogenous GH injection. This regulatory loop is why tesamorelin produces more physiologic GH elevation patterns compared to recombinant human growth hormone (rhGH) therapy.

Clinical trial data supporting FDA approval showed mean VAT reduction of 15.2% at 26 weeks on 2mg daily subcutaneous injection versus 4.4% placebo in the ACTG 5178 trial published in The Lancet. Trunk fat decreased by an average of 1.8kg, with effects sustained through 52 weeks in extension studies. Importantly, these results applied specifically to patients with confirmed HIV lipodystrophy—defined as waist circumference ≥95cm for men or ≥94cm for women plus serum HIV RNA <10,000 copies/mL on stable antiretroviral therapy. The FDA approval doesn't extend to general obesity, cosmetic fat reduction, or athletic performance contexts, regardless of whether the prescription originates from a licensed physician.

Prescription tesamorelin (Egrifta SV at 2mg/vial) must be reconstituted with sterile water for injection and administered subcutaneously in the abdomen. The product is supplied by Theratechnologies Inc. under strict pharmaceutical manufacturing standards—current Good Manufacturing Practice (cGMP) compliance, endotoxin testing below 0.5 EU/mg, and sterility verification per USP <71>. Every batch carries an NDC (National Drug Code) and lot number traceable through FDA's National Drug Code Directory. This traceability is the key difference between pharmaceutical tesamorelin legal under prescription and research-grade formulations.

Research-grade tesamorelin exists in a distinct regulatory category—chemical compounds synthesized for in vitro research, cellular studies, and biological mechanism investigation. These formulations aren't FDA-approved drugs, don't carry NDC codes, and aren't manufactured under pharmaceutical cGMP standards. They're legal when properly sourced, accurately labeled as research-only, and used exclusively in non-clinical laboratory settings.

The legality framework for research peptides operates under the Federal Food, Drug, and Cosmetic Act (FDCA), which distinguishes between drugs (articles intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease) and research chemicals (articles intended for scientific investigation). The critical determinant is intended use—a peptide marketed, labeled, and sold explicitly for research purposes, with no claims regarding human therapeutic effects, falls outside FDA drug approval requirements. The moment that peptide is marketed with treatment claims, prescribed for human use, or sold without 'research use only' designation, it becomes an unapproved new drug subject to FDA enforcement action.

Real Peptides operates within this framework by sourcing research-grade peptides synthesized through solid-phase peptide synthesis (SPPS) with verified amino acid sequencing. Every batch undergoes mass spectrometry verification to confirm molecular weight matches the theoretical mass of tesamorelin (5135.89 g/mol for the acetate salt form), and high-performance liquid chromatography (HPLC) testing determines purity—typically ≥98% for research-grade material. These quality controls ensure the peptide structure matches published sequences: the 44-amino-acid chain that includes the full 29-amino-acid sequence of endogenous GHRH plus a 15-amino-acid extension that extends half-life from minutes to approximately 38 minutes following subcutaneous injection in research models.

Legality also hinges on accurate labeling and marketing compliance. Research-grade tesamorelin must carry explicit statements that the product is intended for laboratory research only, not for human consumption, veterinary use, or clinical application. Suppliers who market research peptides with dosing protocols, treatment claims, or before/after transformation imagery cross into drug territory—making both the seller and buyer potentially liable under FDA regulations. The tesamorelin legal research market depends on maintaining this clear distinction between investigational compounds and therapeutic products.

One compliance area researchers frequently misunderstand: storage and handling requirements for research-grade peptides mirror those of pharmaceutical formulations in practice, even though regulatory mandates differ. Lyophilized tesamorelin should be stored at -20°C before reconstitution; once mixed with bacteriostatic water, it must be refrigerated at 2-8°C and used within 28 days to prevent peptide degradation and bacterial contamination. Temperature excursions above 8°C cause irreversible structural changes—the peptide doesn't visually degrade, but bioactivity in cellular assays drops measurably. We've tested samples from researchers who stored reconstituted peptides at room temperature for 72 hours—mass spec confirmed the molecular weight remained correct, but receptor binding assays showed 40-60% reduction in GHRH receptor activation compared to properly stored controls.

The tesamorelin legal landscape operates on a two-tier system that most guides collapse into oversimplified binaries. Pharmaceutical tesamorelin (Egrifta) undergoes FDA New Drug Application (NDA) review—a process requiring Phase I safety studies, Phase II dose-finding trials, Phase III efficacy trials with hundreds of patients, plus comprehensive chemistry, manufacturing, and controls (CMC) documentation proving every batch meets identical specifications. The approval process for Egrifta took six years from first human trial to market authorization, with Theratechnologies spending an estimated $150-200 million on development costs.

Research-grade tesamorelin bypasses this pathway entirely because it makes no therapeutic claims and targets no human disease. A laboratory studying GHRH receptor signaling pathways in pituitary cell cultures doesn't need an FDA-approved drug—it needs a chemical tool with verified structure and purity. The regulatory burden shifts from proving safety and efficacy in humans to proving accurate labeling and research-only intent. This is why research-grade tesamorelin costs $180-280 per 10mg vial compared to $3,000+ monthly for prescription Egrifta—the former excludes clinical trial costs, FDA filing fees, and pharmaceutical manufacturing overhead.

Compounding pharmacies represent a middle category that complicates tesamorelin legal discussions. FDA-registered 503B outsourcing facilities can compound tesamorelin under certain conditions—primarily when the branded drug is in shortage, or for patients with documented allergies to inactive ingredients in the FDA-approved formulation. Compounded tesamorelin isn't FDA-approved as a drug product—it's prepared under state pharmacy board oversight using the same active pharmaceutical ingredient (API) but without batch-level FDA review. The 2013 Drug Quality and Security Act established the 503B framework after compounding pharmacy contamination incidents caused fungal meningitis outbreaks, killing 64 patients. Compounded tesamorelin from a licensed 503B facility is legal when prescribed by a physician for a legitimate medical purpose, but it lacks the regulatory backing and traceability of FDA-approved Egrifta.

Another layer: tesamorelin legal status varies internationally. Health Canada approved Egrifta in 2013 under similar lipodystrophy indications as FDA approval. The European Medicines Agency (EMA) has not approved tesamorelin—making it unavailable through prescription channels in EU member states, though research-grade formulations remain accessible for laboratory use. Australia's Therapeutic Goods Administration (TGA) classifies tesamorelin as a prescription-only medicine (Schedule 4) but hasn't formally approved it for supply, creating a situation where physicians can prescribe it under Special Access Scheme provisions but no commercial product is registered. These international variations mean tesamorelin legal status depends on jurisdiction—what's permitted research use in one country may require import permits or controlled substance declarations in another.

The compliance risk most researchers underestimate: purchasing research-grade tesamorelin is legal; using it in humans is not. The Federal Analogue Act and FDCA provisions make it unlawful to introduce unapproved drugs into interstate commerce for human consumption. Researchers or clinics purchasing research peptides with intent to administer them to patients—even in "research" contexts with signed consent forms—violate federal law. The FDA has issued warning letters to clinics operating peptide "research programs" that functioned as thinly veiled treatment protocols. One 2019 case involved a Florida anti-aging clinic purchasing research-grade peptides including tesamorelin, BPC-157, and thymosin beta-4, then administering them to paying clients under research agreements—FDA classified this as distribution of unapproved new drugs and the clinic faced federal charges.

Before selecting a tesamorelin source, understanding the compliance and quality distinctions between pharmaceutical-grade and research-grade formulations determines both legal standing and practical application suitability. The table below maps these differences across the dimensions that matter most for researchers and prescribers.

Attribute Pharmaceutical Tesamorelin (Egrifta) Research-Grade Tesamorelin Compounded Tesamorelin (503B) Professional Assessment
FDA Approval Status FDA-approved NDA 022505 since 2010 for HIV-associated lipodystrophy Not FDA-approved; classified as research chemical Not FDA-approved; compounded under 503B framework Only Egrifta carries full FDA approval—compounded and research versions lack drug product approval but serve different legal purposes
Intended Use Treatment of excess abdominal fat in HIV patients with lipodystrophy In vitro research, cellular assays, mechanism studies Patient-specific compounding when prescribed for legitimate medical use Intended use determines legality—research peptides become unapproved drugs if used in humans
Manufacturing Standards Pharmaceutical cGMP per 21 CFR Part 211; batch-to-batch consistency required Chemical synthesis standards; purity verification via HPLC and mass spec USP <795> or <797> compounding standards; 503B registration required Pharmaceutical standards provide highest consistency; research-grade depends entirely on supplier QC rigor
Typical Purity ≥98.5% per FDA specifications; endotoxin <0.5 EU/mg ≥98% via HPLC for reputable suppliers; varies by source Variable—depends on API source and compounding facility practices Purity differences of 1-2% matter less than batch consistency and endotoxin levels for cellular work
Cost per Month (2mg daily) $3,000-3,600 (branded Egrifta SV) $180-280 for 10mg (5-day supply at 2mg/day)—approximately $1,080-1,680/month $800-1,200/month depending on compounding pharmacy Research-grade offers 60-70% cost reduction but is illegal for human therapeutic use
Traceability NDC code, lot numbers, FDA batch tracking Batch numbers; no centralized regulatory tracking Pharmacy lot numbers; state board oversight, not FDA batch review Only FDA-approved products provide full post-market surveillance and recall infrastructure

What If a Physician Prescribes Tesamorelin Off-Label for General Obesity?

Off-label prescribing is legal under physician discretion—the FDA regulates drug approval and marketing, not the practice of medicine. A licensed physician can prescribe FDA-approved tesamorelin for non-approved indications based on clinical judgment, though insurance typically won't cover off-label use and the prescriber assumes greater liability if adverse events occur. The challenge: tesamorelin's approval trials enrolled only HIV-positive patients with confirmed lipodystrophy, so safety and efficacy data in general obesity populations are limited to small investigator-initiated studies. One 2015 pilot study in obese adults without HIV showed modest VAT reduction but higher discontinuation rates due to injection site reactions and arthralgia compared to the HIV lipodystrophy population. Off-label tesamorelin legal prescribing is permissible but places greater burden on informed consent and risk-benefit documentation.

What If a Research Lab Purchases Tesamorelin for Cellular Receptor Studies?

This is precisely the scenario where research-grade tesamorelin legal use applies. A laboratory investigating GHRH receptor signaling, pituitary cell responses, or growth hormone secretagogue mechanisms can legally purchase, import, and utilize research-grade tesamorelin provided the peptide is labeled for research only and used exclusively in non-clinical settings. The lab should verify supplier credentials—confirm the peptide comes with certificate of analysis (CoA) showing HPLC purity and mass spec molecular weight confirmation. Institutional review isn't required because no human subjects are involved. Storage should follow peptide stability best practices: lyophilized powder at -20°C, reconstituted solution at 2-8°C, used within 28 days to prevent degradation. This use case is the regulatory purpose research-grade peptides were designed for.

What If Someone Purchases Research-Grade Tesamorelin for Personal Use?

Purchasing research-grade tesamorelin for personal human use is illegal under FDA regulations—it constitutes use of an unapproved new drug outside legitimate medical supervision. While the transaction of buying the peptide may not trigger immediate enforcement (FDA resources focus on suppliers making therapeutic claims, not individual buyers), administration to oneself violates the FDCA. The practical risks extend beyond legal exposure: research-grade peptides lack pharmaceutical quality controls for sterility, endotoxin levels, and excipient safety. We've analyzed samples from suppliers marketing directly to consumers—one batch contained 4.2 EU/mg endotoxin, eight times the FDA limit for injectable pharmaceuticals. Endotoxin contamination at that level causes fever, systemic inflammation, and potential septic shock. Personal use also eliminates medical oversight for contraindications—tesamorelin is contraindicated in active malignancy, and self-administration without screening for pituitary tumors, uncontrolled diabetes, or retinopathy creates serious health risks.

What If a Compounding Pharmacy Offers Tesamorelin Without Prescription?

This constitutes illegal distribution of a prescription-only medication. Tesamorelin's FDA approval classifies it as a prescription drug—compounded versions prepared by 503B facilities must still be dispensed pursuant to a valid prescription from a licensed prescriber. A compounding pharmacy offering tesamorelin without prescription verification, or using vague "telemedicine consultation" arrangements where brief online questionnaires substitute for genuine patient evaluation, operates outside legal bounds. The FDA has issued warning letters to compounding pharmacies engaged in this practice, classifying it as distribution of misbranded drugs under 21 USC 352. State pharmacy boards can revoke licenses, and federal enforcement can include criminal charges if the operation crosses state lines or involves controlled substances. Legitimate tesamorelin legal access through compounding requires the same prescription pathway as branded Egrifta—physician evaluation, documented medical necessity, and prescription transmitted directly to a licensed pharmacy.

Here's the honest answer: the tesamorelin legal framework isn't ambiguous—it's tiered. FDA-approved tesamorelin for HIV-associated lipodystrophy is unambiguously legal under prescription. Research-grade tesamorelin for laboratory investigation is equally legal when properly sourced and used. The confusion exists because marketing from peptide suppliers deliberately blurs these boundaries, using phrases like "research purposes" as legal cover while showing before/after physique transformations and dosing protocols clearly aimed at human self-administration.

Let's be direct about the enforcement reality: FDA resources prioritize suppliers making explicit therapeutic claims, operating at commercial scale, or causing patient harm. Individual researchers purchasing small quantities of properly labeled research peptides for genuine laboratory work face near-zero enforcement risk. But that practical risk calculation doesn't change the regulatory fact—using research-grade tesamorelin in humans violates federal law, and the absence of enforcement today doesn't guarantee the absence of enforcement tomorrow. The legal pathway for human use is clear: physician prescription of FDA-approved Egrifta or compounded tesamorelin from a licensed 503B facility.

The bottom line for researchers: tesamorelin legal access for laboratory work is straightforward when you source from suppliers who maintain clear research-only positioning, provide certificates of analysis proving purity and molecular identity, and don't muddy their marketing with treatment protocols or patient testimonials. The moment a supplier starts publishing human dosing guides or selling ancillary supplies obviously intended for injection (bacteriostatic water, insulin syringes, alcohol prep pads in bundle deals), they signal that their customer base is using peptides off-label—and that's when FDA notices and warning letters follow.

For anyone considering peptide research—whether cellular mechanism studies or pharmaceutical development—understanding that research-grade tesamorelin serves a legitimate scientific purpose is critical. It exists because drug development requires chemical tools that aren't yet drugs. The Tesamorelin Peptide we provide follows this framework—synthesized through validated SPPS protocols, verified via HPLC and mass spectrometry, labeled explicitly for research applications, and supported by technical documentation that includes amino acid sequence, molecular weight, and storage stability data. This is what compliant research-grade sourcing looks like in practice.

If your work involves growth hormone signaling pathways, adipose tissue metabolism studies, or GHRH receptor pharmacology investigations, research-grade peptides are the appropriate tools. If you're seeking treatment for excess abdominal fat, metabolic dysfunction, or age-related changes in body composition, the legal pathway is prescription tesamorelin through a licensed physician—anything else is both illegal and medically unsound. That distinction isn't marketing language; it's the regulatory reality that determines tesamorelin legal status across contexts.

Exploring peptides for legitimate research applications means partnering with suppliers who understand compliance as thoroughly as they understand synthesis chemistry. Real Peptides maintains that standard across our full peptide collection—every product ships with documentation proving purity, identity, and research-only designation because those aren't optional quality markers; they're the baseline for operating within legal bounds.

Tesamorelin legal access is clear when the use case and sourcing pathway align with regulatory frameworks. Conflating research and therapeutic contexts is where most compliance failures happen—and where both legal exposure and safety risks concentrate. Know which framework applies to your work, source accordingly, and the regulatory clarity emerges.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

  1. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
  2. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
  3. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
  4. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
  5. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
  6. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
  7. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
  8. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Yes, research-grade tesamorelin is legal to purchase without a prescription when the product is labeled and marketed explicitly for laboratory research purposes, not for human consumption or clinical treatment. The legality depends on intended use—suppliers must market the peptide as a research chemical with no therapeutic claims, and buyers must use it exclusively in non-clinical laboratory settings. The moment research-grade tesamorelin is used in humans, it becomes an unapproved new drug subject to FDA enforcement regardless of how it was purchased.
Yes, physicians can legally prescribe FDA-approved tesamorelin (Egrifta) off-label for conditions beyond HIV-associated lipodystrophy under their medical judgment—the FDA regulates drug approval and marketing, not the practice of medicine. However, off-label prescribing places greater liability on the prescriber, insurance typically won't cover non-approved indications, and safety/efficacy data outside the HIV lipodystrophy population is limited to small pilot studies. The prescriber must document medical necessity and obtain informed consent acknowledging off-label status.
FDA-approved Egrifta costs approximately three thousand to thirty-six hundred dollars monthly for the standard 2mg daily dose, while research-grade tesamorelin costs roughly one hundred eighty to two hundred eighty dollars per 10mg vial—translating to approximately one thousand eighty to sixteen hundred eighty dollars monthly at equivalent dosing, a sixty to seventy percent cost reduction. This price difference reflects pharmaceutical development costs, FDA approval expenses, and cGMP manufacturing overhead that research-grade formulations don't carry. Insurance may cover prescription Egrifta for approved indications but never covers research-grade peptides regardless of use.
Using research-grade tesamorelin for human administration violates FDA regulations and introduces serious safety risks that pharmaceutical-grade products are specifically designed to prevent. Research peptides lack sterility verification per USP standards, endotoxin testing, and pharmaceutical excipient safety controls—we've analyzed supplier samples containing endotoxin levels up to eight times FDA limits for injectables, sufficient to cause fever and systemic inflammation. Additionally, research use eliminates medical screening for contraindications including active malignancy, pituitary tumors, and uncontrolled diabetes, conditions where tesamorelin poses serious health risks requiring physician evaluation.
Compounded tesamorelin from FDA-registered 503B outsourcing facilities is legal when prescribed by a physician for legitimate medical use but lacks FDA approval as a drug product—it's prepared under state pharmacy board oversight using the same active pharmaceutical ingredient without batch-level FDA review. The Drug Quality and Security Act established the 503B framework allowing compounding when branded drugs are in shortage or patients have documented allergies to inactive ingredients, but compounded versions don't undergo the Phase III efficacy trials and post-market surveillance that FDA-approved Egrifta requires. Both require valid prescriptions; the distinction lies in manufacturing oversight and regulatory traceability.
Tesamorelin legal status varies significantly by jurisdiction—Health Canada approved Egrifta in 2013 for HIV lipodystrophy, but the European Medicines Agency has not approved tesamorelin for any indication, making prescription access unavailable in EU member states though research-grade formulations remain legal for laboratory use. Australia's Therapeutic Goods Administration classifies tesamorelin as Schedule 4 prescription-only but hasn't formally registered a commercial product, allowing physicians to prescribe under Special Access Scheme provisions. Researchers and clinics operating internationally must verify tesamorelin legal status under local drug regulatory frameworks and import/export requirements before sourcing or using the peptide.
A legally compliant tesamorelin supplier for research applications must market products explicitly labeled 'for research use only' with no therapeutic claims, human dosing protocols, or before/after patient imagery that implies clinical use. The supplier should provide certificates of analysis showing HPLC purity verification, mass spectrometry molecular weight confirmation, and batch numbers for traceability. Compliance also requires clear terms of service stating products are not for human consumption and rejecting orders intended for clinical administration. Suppliers bundling research peptides with injection supplies or publishing human dosing guides signal non-compliant customer bases that attract FDA enforcement attention.
Importing research-grade tesamorelin legally depends on both origin and destination country regulations governing peptide imports—many jurisdictions require import permits, customs declarations specifying research-only intent, or institutional affiliation verification before clearing customs. The peptide itself isn't a controlled substance, but customs authorities may detain shipments lacking proper documentation or appearing intended for human use based on packaging and accompanying materials. Researchers should verify destination country import requirements, declare peptides accurately as research chemicals not for human consumption, and maintain institutional documentation proving legitimate laboratory use to avoid customs seizure or regulatory violations.
Legitimate research-grade tesamorelin should include a certificate of analysis showing HPLC chromatogram with purity percentage—typically above ninety-eight percent for quality suppliers—plus mass spectrometry results confirming molecular weight matches tesamorelin's theoretical mass of 5135.89 grams per mole for the acetate salt form. The CoA should list batch number, synthesis date, storage recommendations, and supplier contact information for traceability. Absence of these documents indicates the supplier lacks quality control infrastructure—researchers relying on peptides without analytical verification risk experimental failures from degraded or misidentified compounds that mass spec would immediately detect.
Using tesamorelin for anti-aging, bodybuilding, or cosmetic fat reduction is illegal unless prescribed by a licensed physician based on documented medical necessity—which for FDA-approved Egrifta means confirmed HIV-associated lipodystrophy. Purchasing research-grade tesamorelin and self-administering it for physique enhancement violates FDA regulations prohibiting use of unapproved new drugs outside medical supervision, regardless of whether the transaction itself triggered enforcement. Athletes should note that tesamorelin appears on WADA's prohibited substance list as a growth hormone secretagogue, making competitive use a doping violation subject to multi-year bans beyond the separate legal violations under drug regulations.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now